Trial Profile
A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Fragile X syndrome; Mental retardation
- Focus Therapeutic Use
- Sponsors Alcobra
- 03 Jul 2016 Status changed from active, no longer recruiting to completed.
- 12 Nov 2015 According to an Alcobra media release, the results from this trial will be sufficient to support a claim of efficacy for the approval of metadoxine.
- 24 Jun 2015 Results published in an Alcobra media release.